全文获取类型
收费全文 | 7250篇 |
免费 | 432篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 219篇 |
妇产科学 | 155篇 |
基础医学 | 880篇 |
口腔科学 | 135篇 |
临床医学 | 525篇 |
内科学 | 1912篇 |
皮肤病学 | 150篇 |
神经病学 | 770篇 |
特种医学 | 183篇 |
外科学 | 1117篇 |
综合类 | 27篇 |
现状与发展 | 1篇 |
预防医学 | 331篇 |
眼科学 | 84篇 |
药学 | 390篇 |
中国医学 | 9篇 |
肿瘤学 | 754篇 |
出版年
2023年 | 62篇 |
2022年 | 95篇 |
2021年 | 209篇 |
2020年 | 103篇 |
2019年 | 157篇 |
2018年 | 167篇 |
2017年 | 135篇 |
2016年 | 181篇 |
2015年 | 165篇 |
2014年 | 213篇 |
2013年 | 287篇 |
2012年 | 403篇 |
2011年 | 384篇 |
2010年 | 253篇 |
2009年 | 209篇 |
2008年 | 361篇 |
2007年 | 396篇 |
2006年 | 390篇 |
2005年 | 367篇 |
2004年 | 347篇 |
2003年 | 288篇 |
2002年 | 267篇 |
2001年 | 239篇 |
2000年 | 257篇 |
1999年 | 190篇 |
1998年 | 74篇 |
1997年 | 76篇 |
1996年 | 77篇 |
1995年 | 56篇 |
1994年 | 49篇 |
1993年 | 36篇 |
1992年 | 129篇 |
1991年 | 117篇 |
1990年 | 101篇 |
1989年 | 93篇 |
1988年 | 82篇 |
1987年 | 83篇 |
1986年 | 69篇 |
1985年 | 68篇 |
1984年 | 83篇 |
1983年 | 47篇 |
1982年 | 33篇 |
1981年 | 31篇 |
1980年 | 27篇 |
1979年 | 42篇 |
1978年 | 28篇 |
1976年 | 29篇 |
1974年 | 17篇 |
1973年 | 17篇 |
1972年 | 16篇 |
排序方式: 共有7722条查询结果,搜索用时 0 毫秒
121.
122.
123.
124.
125.
126.
127.
128.
During the last decades, nuts have attracted the attention of researchers for their potential benefits in cardiovascular prevention. We discuss here some aspects of the assumed beneficial effects of nuts, weighing them against potential harm. Epidemiological observations and controlled intervention trials consistently suggest that nuts consumption is associated with improved serum lipid profile, thus helping decrease cardiovascular risk. Being nuts an energy dense food, their impact on energy balance and body weight should be considered. In particular, the claim that adding nuts to the habitual diet, thus increasing calorie intake, does not cause body fat accumulation still needs evidence and biological plausibility. The potential risk associated with the relatively frequent occurrence of allergic reactions following the consumption of nuts is also discussed. 相似文献
129.
Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects 总被引:2,自引:0,他引:2 下载免费PDF全文
Vaira D Vakil N Rugge M Gatta L Ricci C Menegatti M Leandro G Holton J Russo VM Miglioli M 《Gut》2003,52(11):1543-1547
BACKGROUND AND AIM: There are few data on the course of Helicobacter pylori infection in asymptomatic subjects. The aim of this study was to assess the effect of eradication therapy on the development of dyspeptic and gastro-oesophageal reflux disease in a cohort of asymptomatic individuals observed over a prolonged period. METHODS: A total of 169 blood donors infected with H pylori who had volunteered for studies on eradication in 1990 formed the cohort. To be included in this cohort subjects had to have no symptoms, as determined by a validated symptom questionnaire at the baseline visit. Eighty eight subjects were infected with H pylori while 81 had successfully undergone eradication therapy. Subjects were followed up (annually) using the same symptom questionnaire and in 2000 they underwent repeat endoscopy. RESULTS: Thirteen subjects developed symptoms during follow up. The incidence of symptoms in H pylori positive subjects was 1.893/100 person-years of follow up and in H pylori negative individuals 0.163/100 person-years of follow up. H pylori infected subjects were significantly more likely to develop symptoms (log rank test, p=0.003) as well as those infected with CagA positive strains (log rank test, p=0.017). The development of symptomatic gastro-oesophageal reflux disease was no different in individuals with and without eradication (odds ratio 0.57 (95% confidence interval 0.26-1.24); p=0.163). CONCLUSIONS: H pylori eradication prevents the development of dyspeptic symptoms and peptic ulcer disease in healthy asymptomatic blood donors and is not associated with an increase in the incidence of symptomatic gastro-oesophageal reflux disease. 相似文献
130.
Luciano Rausa Anna Russo Vittorio Gebbia Nicola Gebbia Natale D'Alessandro Sergio Palmeri 《Journal of cancer research and clinical oncology》1991,117(3):266-268
Summary A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcinoma.Abbreviations MMC
mitomycin C
- VDS
vindesine
- L-PAM
melphalan 相似文献